Cooper Companies Q3: Revenue Growth Led by CooperVision; CooperSurgical Suffers Write-offs

The Cooper Companies, Inc. (NYSE: COO) - Snapshot from 10‑Q for quarter ended July 31, 2025

What's happening inside the company
* Top-line growth driven by CooperVision; CooperSurgical showing weakness from a product-line exit and related write-offs.
* Management is continuing M&A integration (obp Surgical, Cook Medical-related instalments) and active share repurchases while maintaining leverage and a large revolver balance.
* A previously disclosed material weakness in IT general controls (CooperSurgical U.S. ERP) remains under remediation - management says controls are not yet effective.

Key financials (facts & figures)
* Net sales (Q3 2025): $1,060.3M vs $1,002.8M year‑ago (Q3).
* Gross profit (Q3): $692.0M vs $663.0M; gross margin ≈65% in Q3 2025 vs 66% in Q3 2024 (decline due to inventory write‑offs related to product exit).
* Operating income (Q3): $175.7M vs $192.5M (Q3 2024).
* Net income (Q3): $98.3M vs $104.7M; diluted EPS Q3: $0.49 vs $0.52.
* Nine months: Net sales $3,027.3M; net income $290.3M; diluted EPS YTD $1.45.
* Cash and cash equivalents (7/31/25): $124.9M; operating cash flow (9 months): $548.2M.
* Total debt (7/31/25): $2,478.3M; long‑term debt $2,431.4M. Revolver outstanding $930.2M at weighted‑avg rate 5.43%; term loan $1,500M at 5.30%.
* Total assets: $12,376.7M; stockholders' equity: $8,353.0M.
* Inventories increased to $881.0M (from $802.7M).
* Goodwill: $3,861.8M; other intangibles, net: $1,635.9M.
* Interest rate swaps: eight contracts, $1.6B notional; foreign currency forwards notional $26.8M.

Segment highlights
* CooperVision: net sales Q3 $718.4M (+6% YoY); operating income Q3 $202.6M (+17% YoY) - growth driven by Biofinity, MyDay, MiSight and geographic gains (EMEA, Americas).
* CooperSurgical: net sales Q3 $341.9M (+4% YoY) but operating income Q3 down to $(4.2)M from $41.3M - inventory and long‑lived asset write‑offs tied to a product‑line exit and higher amortization from 2024 acquisitions.

Positive aspects of the income statement
* Revenue growth across the business (Q3 +6% overall; CooperVision +6%, CooperSurgical +4%).
* Gross profit increased in dollars (Q3 gross profit $692.0M) and nine‑month operating income up (YTD operating income $542.5M vs $507.3M).
* Operating cash flow strengthened significantly (9 months $548.2M vs $441.2M) - supports capex, working capital and buybacks.
* Interest expense declined (Q3 $25.4M vs $28.5M) despite sizable debt - lower rates / lower average balances helped.

Negative aspects of the income statement
* Quarterly net income and operating income both declined year‑over‑year (Q3 net income $98.3M vs $104.7M; operating income $175.7M vs $192.5M).
* Gross margin compressed (65% vs 66%) due to inventory write‑offs tied to a product‑line exit.
* CooperSurgical swung to an operating loss in the quarter (impact of write‑offs and higher amortization).
* Other expense included a notable loss on disposal of a minority investment (nine months included $15.7M loss).
* Effective tax rate increased on a nine‑month basis (35.4% vs 33.6% prior year), reducing after‑tax earnings.

Capital allocation & balance sheet actions
* Share repurchases: Q3 repurchased 0.7M shares for $52.2M (9 months 1.2M shares for $92.8M); $163.6M remains authorized under program.
* Capital expenditures YTD: $264.4M (9 months).
* Acquisitions: obp Surgical (Aug 1, 2024) and prior Cook Medical payments; $47.1M acquisition installment paid YTD.

Risks and governance
* Material weakness in IT general controls for CooperSurgical remains - disclosure controls & procedures currently assessed as not effective.
* High leverage ($2.48B total debt) with large revolver usage ($930.2M) - company remains covenant‑compliant but exposed to interest rate and FX risk (hedged partially).
* Ongoing risks: integration of acquisitions, supply chain (silicone hydrogel components), regulatory changes, and litigation - all disclosed in risk factors.

Bottom line - concise read
* The Cooper Companies is growing sales driven by CooperVision and product momentum, generating stronger operating cash flow. However, near‑term profitability is pressured by CooperSurgical write‑offs, higher SG&A and R&D, margin compressions from inventory actions, and an unresolved IT controls weakness. Balance sheet liquidity is adequate but leverage and ongoing integration risks warrant watching.

If you want, I can produce a 1‑page PDF executive summary, a one‑year trend chart of the key metrics above, or a quick SWOT based on these numbers.